Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation.
Primary biliary cirrhosis (PBC) reoccurs in a proportion of patients following liver transplantation (LT). The aims of our study were to evaluate the risk factors associated with PBC recurrence and determine whether recurrent disease constitutes a negative predictor for survival. One hundred and eight patients receiving LT for end-stage PBC were studied. Recurrent disease was diagnosed in 28 patients (26%). Probability of recurrent PBC at 5 years was 13% and 29% at 10 years with an overall incidence of 3.97 cases per 100 patient years. By univariate Cox analysis use of tacrolimus (HR 6.28, 95% CI, 2.44-16.11, p < 0.001) and mycophenolate mofetil (HR 5.21, 95% CI, 1.89-14.33, p = 0.001) were associated with higher risk of recurrence; whereas use of cyclosporine A (CsA) and azathioprine were associated with reduced risk of recurrence (HR 0.13, 95% CI 0.05-0.35, p < 0.001 and HR 0.27, 95% CI 0.11-0.64, p = 0.003, respectively). In the multivariate Cox analysis, only CsA was independently associated with protection against recurrence (HR 0.17, 95% CI 0.06-0.71, p = 0.02). Five-year probability of survival was 83% and 96%, in patients without and with recurrence (log-rank test, p = 0.3). Although PBC transplant recipients receiving CsA have a lower risk of disease recurrence, the development of recurrent PBC did not impact on long-term patient survival.
Division of Gastroenterology & Liver Unit, Zeidler Ledcor Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.
A J
AJ
Montano-Loza
Division of Gastroenterology & Liver Unit, Zeidler Ledcor Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.
S
S
Wasilenko
Division of Gastroenterology & Liver Unit, Zeidler Ledcor Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.
J
J
Bintner
Division of Gastroenterology & Liver Unit, Zeidler Ledcor Centre, University of Alberta Hospital, Edmonton, Alberta, Canada.
A L
AL
Mason
D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000503:physiopathology / Q000517:prevention & control*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011336:Probability; D012008:Recurrence
D016572:Cyclosporine